Answers are grounded in this paper and cite their sources.
Cellular immunotherapy CAR-T (Chimeric Antigen Receptor T-Cell, or T-cells with a chimeric antigen receptor) is an advanced approach to the treatment of oncological diseases. Currently, CAR-Ttherapy has shown high efficiency in the treatment of oncohematological diseases. At the same time, numerous attempts to create CAR-T-constructs for the treatment of solid tumors, in particular breast cancer (BC), have not demonstrated significant clinical efficacy. It is assumed that the key to solving these problems lies in the development and implementation of new genetic engineering strategies.The purpose of this review was to summarize and systematize existing studies with CAR technology. In this paper, we summarize potential targets for the treatment of BC, detail the existing limitations of using these technologies and identify important future trends in this area.
No takes yet. Share an insight, caveat, or question.
Сорокина et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: